Skip to main content
  1. Market Insights
  2. Health
  3. Pharmaceuticals

Anti-Rheumatic Drugs - APAC

APAC
  • Revenue in the Anti-Rheumatic Drugs market is projected to reach US$5.99bn in 2024.
  • Revenue is expected to show an annual growth rate (CAGR 2024-2028) of 1.18%, resulting in a market volume of US$6.28bn by 2028.
  • In global comparison, most revenue will be generated United States (US$34.70bn in 2024).

Definition:
The market Anti-Rheumatic Drugs includes medication for the treatment of the inflammatory disease rheumatism. Due to the high prevalence of rheumatism and the large size of the market, this section of immune diseases is treated as a separate market. Both steroidal and non-steroidal anti-rheumatics are included. Disease-modifying rheumatic drugs (DMARDs), such as tumor necrosis factor inhibitors (a type of biologic DMARD), are particularly important in terms of commerciality.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: AbbVie, Johnson & Johnson, Pfizer, Amgen, Roche

In-Scope

  • Drugs to treat rheumatism
  • Steroidal (corticosteroids) and non-steroidal anti-rheumatics
  • Disease-modifying antirheumatic drugs (DMARDs)
  • Tumor necrosis factor (TNF) inhibitors

Out-Of-Scope

  • Drugs to treat other autoimmune diseases (such as multiple sclerosis or psoriasis)
  • Analgetics for general use (such as paracetamol)
  • Treatment of osteoarthritis
Pharmaceuticals

Pharmaceuticals

Related markets:
Anti-Rheumatic Drugs: market data & analysis - Cover

Market Insights report

Anti-Rheumatic Drugs: market data & analysis

Study Details
    methodology

    Download PDF

    FAQs and more info on the methodology

    Revenue

    Notes: Data was converted from local currencies using average exchange rates of the respective year.

    Most recent update: Mar 2024

    Source: Statista Market Insights

    Analyst Opinion

    For the past years, Anti-Rheumatic Drugs has been the second largest section of the Pharmaceuticals market. While most patients are treated with painkillers and cheaper anti-inflammatory drugs, the overall revenue is dominated by expensive drugs that are taken by only a fraction of affected patients.

    The market size is projected to decrease because of biosimilar competition for the market-leading product Humira by AbbVie. The drop in 2019 reflects the emergence of biosimilars outside of the U.S., while the decrease expected to occur towards the end of the time series is linked to the loss of exclusivity in the U.S.

    Global Comparison

    Most recent update: Mar 2024

    Source: Statista Market Insights

    Methodology

    Data coverage:

    Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

    Modeling approach / Market size:

    Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

    Forecasts:

    In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

    Additional notes:

    Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

    Health

    Access more Market Insights on Health topics with our featured report

    Anti-Rheumatic Drugs: market data & analysis - BackgroundAnti-Rheumatic Drugs: market data & analysis - Cover

    Explore more high-quality data on related topic

    Global pharmaceutical industry - statistics & facts

    The global pharmaceutical industry has experienced significant growth during the past two decades, with revenues totaling around 1.6 trillion U.S. dollars in 2023. With growth like that, the industry's size is now comparable to the gross domestic products (GDPs) of countries like Spain, Mexico, or Australia.
    More data on the topic
    Revenue of the worldwide pharmaceutical market in 2023
    1.6tr USD
    Revenue share of the North American pharmaceutical market in 2023
    53.3%
    Pharmaceutical sales in oncologics in 2023
    214bn USD

    Contact

    Get in touch with us. We are happy to help.